Skip to main content

Advertisement

SpringerLink
Log in

Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy

  • Lung Cancer (H Borghaei, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Immunotherapy has revolutionized the treatment of non-surgical stage III and stage IV non-small cell lung cancer (NSCLC). Here, we review emerging data on the safety, feasibility, and efficacy of neoadjuvant immunotherapy in the setting of earlier stage surgically resectable lung cancer.

Recent Findings

Several small studies support the safety and feasibility of neoadjuvant immunotherapy, noting similar perioperative rates of morbidity and mortality compared with historical controls. Data from several phase II trials have shown high rates of major pathologic response (MPR), though it is unclear if this will correlate with a survival benefit. Phase III trials of neoadjuvant immunotherapy alone or in combination with chemotherapy are ongoing.

Summary

Neoadjuvant immunotherapy offers a promising treatment modality in earlier stage NSCLC patients. Results of ongoing phase II and phase III trials will be essential in determining how to best integrate this treatment modality in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

    Article  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.

    Article  PubMed  Google Scholar 

  3. Wahbah M, Boroumand N, Castro C, El-Zeky F, Eltorky M. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol. 2007;11(2):89–96. https://doi.org/10.1016/j.anndiagpath.2006.04.006.

    Article  PubMed  Google Scholar 

  4. Zhang Y, Ren JS, Huang HY, Shi JF, Li N, Dai M. International trends in lung cancer incidence from 1973 to 2007. Cancer Med. 2018;7(4):1479–89. https://doi.org/10.1002/cam4.1359.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P, et al. The IASLC lung Cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung Cancer. J Thorac Oncol. 2017;12(7):1109–21. https://doi.org/10.1016/j.jtho.2017.04.011.

    Article  PubMed  Google Scholar 

  6. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. https://doi.org/10.1016/j.jtho.2015.09.009.

    Article  PubMed  Google Scholar 

  7. Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg. 2013;145(1):75–81; discussion 81-82. https://doi.org/10.1016/j.jtcvs.2012.09.030.

    Article  PubMed  Google Scholar 

  8. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10(7):990–1003. https://doi.org/10.1097/JTO.0000000000000559.

    Article  PubMed  Google Scholar 

  9. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest. 2011;140(6):1494–502. https://doi.org/10.1378/chest.10-3279.

    Article  PubMed  Google Scholar 

  10. Williams BA, Sugimura H, Endo C, Nichols FC, Cassivi SD, Allen MS, et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg. 2006;81(3):1021–7. https://doi.org/10.1016/j.athoracsur.2005.09.020.

    Article  PubMed  Google Scholar 

  11. Institute NC. Cancer stat facts: lung and bronchus cancer. 2019. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed 29 Dec 2019.

  12. Rossi L, Stevens D, Pierga JY, Lerebours F, Reyal F, Robain M, et al. Impact of adjuvant chemotherapy on breast cancer survival: a real-world population. PLoS One. 2015;10(7):e0132853. https://doi.org/10.1371/journal.pone.0132853.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378(13):1177–88. https://doi.org/10.1056/NEJMoa1713709.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311(7010):899–909.

  15. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–60. https://doi.org/10.1056/NEJMoa031644.

    Article  PubMed  Google Scholar 

  16. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589–97. https://doi.org/10.1056/NEJMoa043623.

    Article  CAS  PubMed  Google Scholar 

  17. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552–9. https://doi.org/10.1200/JCO.2007.13.9030.

    Article  PubMed  Google Scholar 

  18. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017;18(12):1610–23. https://doi.org/10.1016/S1470-2045(17)30691-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Vansteenkiste J, Crinò L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25(8):1462–74. https://doi.org/10.1093/annonc/mdu089.

    Article  CAS  PubMed  Google Scholar 

  20. Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario clinical practice guideline update. J Clin Oncol. 2017;35(25):2960–74. https://doi.org/10.1200/JCO.2017.72.4401.

    Article  PubMed  Google Scholar 

  21. Network NCC. Non-small cell lung cancer (Version 2.2020). 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 17 Jan 2020.

  22. Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, et al. SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor–mutant non–small-cell lung cancer. J Clin Oncol. 2019;37(2):97–104. https://doi.org/10.1200/JCO.18.00131.

    Article  CAS  PubMed  Google Scholar 

  23. Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139–48. https://doi.org/10.1016/S1470-2045(17)30729-5.

    Article  CAS  PubMed  Google Scholar 

  24. Gerber DE, Oxnard GR, Govindan R. ALCHEMIST: bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin Pharmacol Ther. 2015;97(5):447–50. https://doi.org/10.1002/cpt.91.

    Article  CAS  PubMed  Google Scholar 

  25. Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer. 2018;19(4):e533–e6. https://doi.org/10.1016/j.cllc.2018.04.004.

    Article  CAS  PubMed  Google Scholar 

  26. Solomon BJ, Ahn JS, Barlesi F, Dziadziuszko R, Nishio M, Shaw AT, et al. ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37(suppl; abstr):TPS8569. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS8569.

    Article  Google Scholar 

  27. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.

    Article  CAS  PubMed  Google Scholar 

  28. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92. https://doi.org/10.1056/NEJMoa1801005.

    Article  CAS  PubMed  Google Scholar 

  29. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51. https://doi.org/10.1056/NEJMoa1810865.

    Article  CAS  PubMed  Google Scholar 

  30. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301. https://doi.org/10.1056/NEJMoa1716948.

    Article  CAS  PubMed  Google Scholar 

  31. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31. https://doi.org/10.1056/NEJMoa1910231.

    Article  CAS  PubMed  Google Scholar 

  32. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–50. https://doi.org/10.1056/NEJMoa1809697.

    Article  CAS  PubMed  Google Scholar 

  33. Gray JE, Villegas AE, Daniel DB, Vicente D, Murakami S, Hui R, et al. Three-year overall survival update from the PACIFIC trial. J Clin Oncol. 2019;37(suppl; abstr):8526. https://doi.org/10.1200/JCO.2019.37.15_suppl.8526.

    Article  Google Scholar 

  34. Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer. 2005;47(3):385–94. https://doi.org/10.1016/j.lungcan.2004.08.016.

    Article  PubMed  Google Scholar 

  35. Nelson DB, Mehran RJ, Mitchell KG, Correa AM, Sepesi B, Antonoff MB, et al. Enhanced recovery after thoracic surgery is associated with improved adjuvant chemotherapy completion for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158(1):279–86.e1. https://doi.org/10.1016/j.jtcvs.2019.03.009.

    Article  PubMed  Google Scholar 

  36. Pisters KM, Ginsberg RJ, Giroux DJ, Putnam JB, Kris MG, Johnson DH, et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality lung oncology team. J Thorac Cardiovasc Surg. 2000;119(3):429–39. https://doi.org/10.1016/s0022-5223(00)70120-6.

    Article  CAS  PubMed  Google Scholar 

  37. Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28(19):3138–45. https://doi.org/10.1200/JCO.2009.27.6204.

    Article  CAS  PubMed  Google Scholar 

  38. • Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42–50. https://doi.org/10.1016/S1470-2045(13)70334-6. This study links major pathologic response after neoadjuvant therapy to survival outcomes in non-small cell lung cancer.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1):2724. https://doi.org/10.21417/B7ZW6H.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–99. https://doi.org/10.1158/2159-8290.CD-16-0577.

    Article  CAS  PubMed  Google Scholar 

  41. Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, et al. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg. 2018;106(1):178–83. https://doi.org/10.1016/j.athoracsur.2018.02.030.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Yang CJ, McSherry F, Mayne NR, Wang X, Berry MF, Tong B, et al. Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for non-small cell lung cancer. Ann Thorac Surg. 2018;105(3):924–9. https://doi.org/10.1016/j.athoracsur.2017.09.030.

    Article  PubMed  Google Scholar 

  43. •• Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–86. https://doi.org/10.1056/NEJMoa1716078. This pilot trial evaluated the safety and feasibility of neoadjuvant nivolumab in resectable NSCLC. This treatment was found to have few side-effects and no surgical delays. Of those resected, 45% had MPR, including a number who had shown no radiographic response prior to resection.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. •• Bott MJ, Yang SC, Park BJ, Adusumilli PS, Rusch VW, Isbell JM, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158(1):269–76. https://doi.org/10.1016/j.jtcvs.2018.11.124. Report of sugical outcomes after neoadjuvant nivolumab demonstrate safety, but more complicated surgeries due to hilar inflammation and fibrosis.

    Article  CAS  PubMed  Google Scholar 

  45. Puri V, Patel A, Majumder K, Bell JM, Crabtree TD, Krupnick AS, et al. Intraoperative conversion from video-assisted thoracoscopic surgery lobectomy to open thoracotomy: a study of causes and implications. J Thorac Cardiovasc Surg. 2015;149(1):55–61, 2.e1. https://doi.org/10.1016/j.jtcvs.2014.08.074.

    Article  PubMed  Google Scholar 

  46. Lee JM, Martin LW, Yang SC. Discussions in cardiothoracic treatment and care: what the surgeon needs to know about checkpoint inhibition in immunotherapy. Semin Thorac Cardiovasc Surg. 2019;32:327–36. https://doi.org/10.1053/j.semtcvs.2019.12.009.

    Article  PubMed  Google Scholar 

  47. Reuss JE, Smith KN, Anagnostou V, Zhang J, Zahurak M, Caushi J, et al. Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response. J Clin Oncol. 2019;37(15_suppl):8524. https://doi.org/10.1200/JCO.2019.37.15_suppl.8524.

    Article  Google Scholar 

  48. Kwiatkowski DJ, Rusch VW, Chaft JE, Johnson BE, Nicholas A, Wistuba II, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). J Clin Oncol. 2019;37(15_suppl):8503. https://doi.org/10.1200/JCO.2019.37.15_suppl.8503.

    Article  Google Scholar 

  49. Cascone T, William WN, Weissferdt A, Lin HY, Leung CH, Carter BW, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J Clin Oncol. 2019;37(suppl; abstr):8504. https://doi.org/10.1200/JCO.2019.37.15_suppl.8504.

    Article  Google Scholar 

  50. •• Provencio M, Nadal E, Insa A, Garcia-Campelo R, Casal Rubio J, Domine M, et al. Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment. J Clin Oncol. 2019;37(suppl; abstr):8509. https://doi.org/10.1200/JCO.2019.37.15_suppl.8509. This phase II trial of neoadjuvant chemotherapy and nivolumab reported remarkably high major pathologic response and pathologic complete response rates for patients with stage IIIA non-small cell lung cancer.

    Article  Google Scholar 

  51. Shu CA, Grigg C, Chiuzan C, Garofano RF, Patel V, Hernandez S, et al. Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC). J Clin Oncol. 2018;36(15_suppl):8532. https://doi.org/10.1200/JCO.2018.36.15_suppl.8532.

    Article  Google Scholar 

  52. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

    Article  CAS  PubMed  Google Scholar 

  53. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20. https://doi.org/10.1158/1078-0432.CCR-09-1624.

    Article  CAS  PubMed  Google Scholar 

  54. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19(14):3936–43. https://doi.org/10.1158/1078-0432.CCR-13-0895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e52. https://doi.org/10.1016/S1470-2045(17)30074-8.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Administration UFaD. Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. Silver Spring: US Department of Health and Human Services; 2014.

    Google Scholar 

  57. Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853–60. https://doi.org/10.1093/annonc/mdy218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, et al. Local consolidative therapy Vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–65. https://doi.org/10.1200/JCO.19.00201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of Virginia, PO Box 800716, Charlottesville, VA, 22908, USA

    Ryan D. Gentzler & David O. Riley

  2. Division of Thoracic Cardiovascular Surgery, University of Virginia, Charlottesville, VA, USA

    Linda W. Martin

Authors
  1. Ryan D. Gentzler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David O. Riley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linda W. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryan D. Gentzler.

Ethics declarations

Conflict of Interest

Ryan D. Gentzler has received research funding from Jounce Therapeutics, Helsinn, Celgene, Bristol-Myers Squibb, Pfizer, Takeda, and Merck; and has received compensation from AstraZeneca, Pfizer, Merck, ARIAD, and Bristol-Myers Squibb for service as a consultant. David O. Riley and Linda W. Martin declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lung Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gentzler, R.D., Riley, D.O. & Martin, L.W. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. Curr Oncol Rep 22, 109 (2020). https://doi.org/10.1007/s11912-020-00969-w

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-020-00969-w

Keywords

Search

Navigation